Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

• DOI: 10.3892/or.2020.7877
• Publication Date: 2020-12-01T14:01:42Z
• Authors: Mariana Concentin...; Isabella Dos Sant...; Luciana Ferreira; Leticia Batista R...; Raquel Maia; Gabriela Nestal D...; Etel Gimba
• Keywords: Osteopontin; Viability assay

Osteopontin (OPN) is upregulated in several types of tumor and has been associated with chemoresistance. However, the contribution OPN splicing isoforms (OPN‑SIs) to chemoresistance requires further investigation. The present study aimed evaluate expression patterns each tested OPN‑SI cisplatin (CDDP)‑resistant ovarian carcinoma cell lines, focusing on role OPN‑c isoform (OPNc) drug resistance. ACRP cancer cells resistant CDDP, as well their parental line A2780, were used. Analyses transcriptional OPN‑SIs, epithelial‑mesenchymal transition (EMT) markers EMT‑related cytokines performed using reverse transcription‑quantitative PCR. OPNc was silenced anti‑OPNc DNA oligomers stably overexpressed by transfecting A2780 a mammalian vector containing full length cDNA. Functional assays determine proliferation, viability colony formation. results demonstrated that among three most transcript compared cells. In addition, levels P‑glycoprotein multidrug transporter CDDP‑resistant those knockdown sensitized CDDP treatment downregulated P‑gp negative control group. Additionally, silencing impaired proliferative formation abilities, reversed EMT Notably, although stable overexpression resulted increased it notably sensitivity transfected vector. These suggested may represent putative approach sensitize chemotherapeutic agents.